You are viewing the site in preview mode

Skip to main content

Table 4 Change (delta [δ]a,b, %) in computed tomography (CT) derived abdominal obesity markers in relation to clinicopathological features at primary diagnosis in nfollow−up=152 endometrial cancer patients

From: Abdominal fat distribution in endometrial cancer: from diagnosis to follow-up

 

n (%)

δTAVa

median

[95% CI]

p*

δVAVa

median

[95% CI]

p*

δSAVa

median

[95% CI]

p*

δVAV%b

median

[95% CI]

p*

δWCa

median

[95% CI]

p*

Age

  

0.004

 

0.01

 

0.009

 

0.41

 

< 0.001

 < 69 years

67

-9% [-13, -3]

 

-17% [-20, -12]

 

-7% [-10, -1]

 

-3% [-3, -1]

 

4% [1, 5]

 

 ≥ 69 years

85

-16% [-19, -12]

 

-23% [-27, -19]

 

-11% [-16, -8]

 

-3% [-4, -2]

 

-1% [-2, 1]

 

Diabetesc

  

0.25

 

0.58

 

0.23

 

0.49

 

0.09

 No

130

-13% [-16, 10]

 

-19% [-23, -16]

 

-9% [-12, -6]

 

-3 [-3, -2]

 

2% [0, 3]

 

 Yes

21

-17% [-27, -7]

 

-22% [-31, -14]

 

-16% [-24, -4]

 

-3 [-4, -1]

 

-3% [-5, 3]

 

Lymph node metastasesd

  

0.90

 

0.58

 

0.69

 

0.36

 

0.99

 no

78

-13% [-16, -10]

 

-19% [-24, -12]

 

-9% [-13, -7]

 

-2% [-3, -1]

 

1% [0, 4]

 

 yes

22

-11% [-20, -4]

 

-21% [-30, -16]

 

-10% [-16, 6]

 

-4% [-5, -2]

 

2% [-1, 3]

 

Myometrial invasionc

  

0.56

 

0.18

 

0.96

 

0.18

 

0.45

 < 50%

68

-13% [-15, -8]

 

-18% [-20, -13]

 

-9% [-12, -6]

 

-3% [-3, -2]

 

2% [1, 3]

 

 ≥ 50%

76

-12% [-17, -7]

 

-22% [-26, -14]

 

-8% [-13, -5]

 

-3% [-4, -2]

 

1% [-2, 4]

 

Lymphovascular space invasionc

  

0.05

 

0.004

 

0.19

 

0.07

 

0.10

 No

103

-11% [-14, -6]

 

-18% [-20, -12]

 

-8% [-11, -5]

 

-2% [-3, -1]

 

2% [1, 3]

 

 Yes

34

-16% [-23, -11]

 

-26% [-37, -19]

 

-9% [-22, -5]

 

-4% [-6, -2]

 

1% [-3, 3]

 

Histological subtype

  

0.05

 

0.007

 

0.09

 

0.04

 

0.38

 EEC grade 1–2

64

-10% [-13, -5]

 

-14% [-20, -9]

 

-7% [-10, -5]

 

-2% [-3, -1]

 

2% [0, 4]

 

 EEC grade 3

26

-16% [-20, -5]

 

-20% [-27, -13]

 

-9% [-20, 6]

 

-2% [-4, -1]

 

1% [-4, 3]

 

 NEEC

62

-17% [-21, -13]

 

-25% [-29, -19]

 

-12% [-17, -7]

 

-3% [-4, -3]

 

1% [-1, 3]

 

FIGO stage

  

0.46

 

0.11

 

0.75

 

0.10

 

0.55

 I-II

105

-12% [-15, -10]

 

-18% [-22, -14]

 

-9% [-12, -7]

 

-2% [-3, -1]

 

1% [0, 3]

 

 III-IV

47

-16% [-22 -7]

 

-23% [-29, -18]

 

-11% [-19, -1]

 

-4% [-5, -3]

 

1% [-3 4]

 
  1. CI, confidence interval; EEC, endometrioid endometrial carcinoma; FIGO, International Federation of Gynecology and Obstetrics; NEEC, non-endometrioid endometrial carcinoma; SAV, subcutaneous abdominal fat volume; TAV, total abdominal fat volume; VAV, visceral abdominal fat volume; VAV%, visceral-to-total fat percentage; WC, waist circumference
  2. aDelta[δ] TAV, VAV, SAV and WC defined as ((follow-up - primary)/primary))
  3. bDelta[δ] VAV% defined as (follow-up - primary)
  4. cNumber (n) of patients with variables missing/not assessed in nfollow−up: diabetes (1), myometrial invasion (8), lymphovascular space invasion (15)
  5. dLymphadenectomy in 100/152 of the patients in nfollow−up
  6. *Mann-Whitney U-test for two categories (exact p). Kruskal-Wallis equality-of-populations rank test for three categories. p < 0.05 marked in bold
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us